4 results
The objectives of this study are to demonstrate that Nepafenac Ophthalmic Suspension, 0.3% is not inferior to Nepafenac Ophthalmic Suspension, 0.1% (NEVANAC®); Nepafenac Ophthalmic Suspension, 0.3% is superior to Nepafenac 0.3% Vehicle and NEVANAC…
The aim of this study is to investigate the effect of the intranasal cooling (RhinoChill System) on the severity and frequency of withdrawal headache and associated symptoms in the first 7 days during standard care treatment for detoxification of…
The aim of this study is to investigate the effect of the intranasal cooling (RhinoChill System) on the severity and frequency of withdrawal headache and associated symptoms in the first 7 days during standard care treatment for detoxification of…
Primary objective• To explore the feasibility of multiple dose administration of oxybutynin via the MedRing OAB system in an outpatient setting.• Safety and tolerability of 28 days of intravaginal dosing of oxybutynin via the MedRingSecondary…